The modifier signals the intent
The reconstitution and administration of injectable medicines in the UK must be performed by, or under the direct supervision of, a qualified healthcare professional, following the product's SmPC and in accordance with NHS and NPSA guidance on the safer use of injectable medicines
The compound suppresses fibrinogen expression (linked to cardiovascular risk) and reduces TGF-beta-driven fibrosis signaling
Potential risks include: Infection risk if injections are administered in non-clinical settings without appropriate sterile technique Allergic reactions to any component of the formulation Liver toxicity theoretical concern with excessive methionine or choline Drug interactions particularly if combined with other supplements or medications Unknown long-term effects due to absence of longitudinal safety data The MHRA advises caution with unlicensed injectable products, as quality, purity, and sterility cannot be guaranteed
If stubborn particles remain, let the vial sit for a few minutes and roll again
FAQs Frequently asked questions The FDA does not currently approve the BPC-157 peptide for medical use